

# Europe Nucleic Acid Therapeutics CDMO Market: Analysis and Forecast, 2023-2033

<https://marketpublishers.com/r/EDF99B8B9E35EN.html>

Date: February 2024

Pages: 104

Price: US\$ 2,950.00 (Single User License)

ID: EDF99B8B9E35EN

## Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 1-5 working days.

### Introduction to Europe Nucleic Acid Therapeutics CDMO Market

The Europe nucleic acid therapeutics CDMO market was valued at \$1.27 billion in 2023 and is expected to reach \$3.88 billion by 2033, growing at a CAGR of 11.80% during the forecast period 2023-2033. The nucleic acid therapeutics CDMO market is experiencing growth due to various factors, these include increasing demand for nucleic acid therapeutics in treating chronic and genetic illnesses, advancements in manufacturing processes by Contract Development and Manufacturing Organizations (CDMOs), a surge in FDA approvals for such therapeutics, and growing investments in expanding CDMO manufacturing capacities.

### Market Introduction

The Europe nucleic acid therapeutics Contract Development and Manufacturing Organization (CDMO) market is witnessing significant growth. This expansion is driven by a rising demand for nucleic acid-based treatments to address chronic and genetic diseases prevalent in the region. Additionally, advancements in manufacturing processes by CDMOs are enhancing the production efficiency and scalability of nucleic acid therapeutics. The region has also seen an uptick in FDA approvals for these therapies, indicating growing acceptance and adoption. Moreover, increased investments in expanding CDMO manufacturing facilities across Europe are further fueling market growth. This dynamic landscape underscores the region's commitment to

innovation and healthcare advancement, positioning Europe as a key player in the global nucleic acid therapeutics CDMO market.

Market Segmentation:

Segmentation 1: by Chemical Synthesis Method

Solid-Phase Oligonucleotide Synthesis

Liquid-Phase Oligonucleotide Synthesis

Segmentation 2: by Country

Germany

U.K.

France

Italy

Spain

Rest-of-Europe

How can this report add value to an organization?

**Product/Innovation Strategy:** The Europe nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as chemical synthesis method and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

**Competitive Strategy:** Key players in the Europe nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.

## Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

AGC Biologics

BACHEM

Eurofins Scientific

LGC Science Group Holdings Limited

Merck KGaA

## Contents

Executive Summary  
Scope of the Study  
Research Methodology

### 1 MARKET

#### 1.1 Market Outlook

- 1.1.1 Market Overview
- 1.1.2 Product Definition
- 1.1.3 Inclusion and Exclusion Criteria
- 1.1.4 Key Findings

#### 1.2 Industry Outlook

- 1.2.1 Key Trends
  - 1.2.1.1 Significant Number of Collaborations among Market Players
  - 1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO

#### Manufacturing Units

- 1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing

#### Environment

- 1.2.2 Opportunity Assessment
- 1.2.3 Patent Analysis
  - 1.2.3.1 Awaited Technological Developments
  - 1.2.3.2 Patent Filing Trend (by Country)
  - 1.2.3.3 Patent Filing Trend (by Year)
- 1.2.4 Production Capability
- 1.2.5 Preferred Techniques By CDMO
  - 1.2.5.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
  - 1.2.5.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
  - 1.2.5.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
- 1.2.6 Factors Considered While Outsourcing To CDMO.
- 1.2.7 Regulatory Framework

#### 1.3 Impact of COVID-19 on the Nucleic Acid Therapeutics CDMO

- 1.3.1 Pre-COVID-19 Phase
- 1.3.2 During COVID-19
- 1.3.3 Post-COVID-19 Phase
  - 1.3.3.1 Impact on Demand and Supply

#### 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape

#### 1.5 Significant Usage of Nucleic Acid in Therapeutics

## 1.6 Types of Nucleic Acid Synthesized for Therapeutics

1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers

1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)

1.6.3 MicroRNAs (miRNAs)

1.6.4 RNA Aptamers and RNA Decoys

1.6.5 Ribozymes

1.6.6 Circular RNAs

## 1.7 Business Dynamics

1.7.1 Impact Analysis

1.7.2 Business Drivers

1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases

1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics

1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs

1.7.3 Business Restraints

1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification

1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic

1.7.4 Business Opportunities

1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.

1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

## 2 NUCLEIC ACID THERAPEUTICS CDMO MARKET (BY REGION)

### 2.1 Europe Nucleic Acid Therapeutics CDMO Market

2.1.1 Key Findings

2.1.2 Market Dynamics

2.1.2.1 Impact Analysis

2.1.3 Market Sizing and Forecast

2.1.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

2.1.3.2 Europe Nucleic Acid Therapeutics CDMO Market (by Country)

2.1.3.2.1 Germany

2.1.3.2.1.1 Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

2.1.3.2.2 U.K.

2.1.3.2.2.1 U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

2.1.3.2.3 France

2.1.3.2.3.1 France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

2.1.3.2.4 Spain

2.1.3.2.4.1 Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

2.1.3.2.5 Italy

2.1.3.2.5.1 Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

2.1.3.2.6 Rest-of-Europe

2.1.3.2.6.1 Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

### **3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES**

#### 3.1 Competitive Benchmarking

##### 3.1.1 Key Strategies and Developments

###### 3.1.1.1 Funding Activities

###### 3.1.1.2 New Offerings

###### 3.1.1.3 Mergers and Acquisitions

###### 3.1.1.4 Partnerships and Collaborations

###### 3.1.1.5 Business Expansions

###### 3.1.1.6 Regulatory and Legal Activities

##### 3.1.2 Market Share Analysis

##### 3.1.3 Visual Graphics of Key Companies

#### 3.2 Company Profile

##### 3.2.1 AGC Biologics

###### 3.2.1.1 Company Overview

###### 3.2.1.2 Role of AGC Biologics in the Nucleic Acid Therapeutics CDMO Market

###### 3.2.1.3 Financials

###### 3.2.1.4 Recent Developments

###### 3.2.1.5 Analyst Perspective

##### 3.2.2 BACHEM

###### 3.2.2.1 Company Overview

###### 3.2.2.2 Role of BACHEM in the Nucleic Acid Therapeutics CDMO Market

###### 3.2.2.3 Financials

###### 3.2.2.4 Recent Developments

3.2.2.5 Analyst Perspective

3.2.3 Eurofins Scientific

3.2.3.1 Company Overview

3.2.3.2 Role of Eurofins Scientific in the Nucleic Acid Therapeutics CDMO Market

3.2.3.3 Financials

3.2.3.4 Recent Developments

3.2.3.5 Analyst Perspective

3.2.4 LGC Science Group Holdings Limited

3.2.4.1 Company Overview

3.2.4.2 Role of LGC Science Group Holdings Limited in the Nucleic Acid  
Therapeutics CDMO Market

3.2.4.3 Recent Developments

3.2.4.4 Analyst Perspective

3.2.5 Merck KGaA

3.2.5.1 Company Overview

3.2.5.2 Role of Merck KGaA in the Nucleic Acid Therapeutics CDMO Market

3.2.5.3 Financials

3.2.5.4 Recent Developments

3.2.5.5 Analyst Perspective

## List Of Figures

### LIST OF FIGURES

Figure 1: Services Offered by CDMOs

Figure 2: Europe Nucleic Acid Therapeutics CDMO Market, Impact Analysis

Figure 3: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033

Figure 4: Nucleic Acid Therapeutics CDMO Market (by Region), \$Billion, 2022 and 2033

Figure 5: Europe Nucleic Acid Therapeutics CDMO Market: Research Methodology

Figure 6: Primary Research Methodology

Figure 7: Bottom-Up Approach (Segment-Wise Analysis)

Figure 8: Top-Down Approach (Segment-Wise Analysis)

Figure 9: Significant Number of Collaborations among Market Players in Nucleic Acid Therapeutics CDMO Market, 2019-2023

Figure 10: Core CDMO Services

Figure 11: Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033

Figure 12: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023

Figure 13: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December 2022

Figure 14: Synthesis Capabilities of Key Companies

Figure 15: Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis

Figure 16: Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis

Figure 17: Preferred Techniques by CDMOs for Nucleic Acid Purification

Figure 18: Factors considered while outsourcing to CDMO.

Figure 19: Nucleic Acid Therapeutics CDMO Market, Impact Analysis

Figure 20: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in \$Million, 2018-2021

Figure 21: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Nucleic Acid Therapeutics CDMO Market, 2018-2020

Figure 22: Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033

Figure 23: Europe Nucleic Acid Therapeutics CDMO Market, \$Billion, 2022-2033

Figure 24: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), \$Million, 2022-2033

Figure 25: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033

Figure 26: Germany Nucleic Acid Therapeutics CDMO Market, \$Billion, 2022-2033



Figure 27: Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), \$Million, 2022-2033

Figure 28: U.K. Nucleic Acid Therapeutics CDMO Market, \$Billion, 2022-2033

Figure 29: U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), \$Million, 2022-2033

Figure 30: France Nucleic Acid Therapeutics CDMO Market, \$Billion, 2022-2033

Figure 31: France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), \$Million, 2022-2033

Figure 32: Spain Nucleic Acid Therapeutics CDMO Market, \$Billion, 2022-2033

Figure 33: Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), \$Million, 2022-2033

Figure 34: Italy Nucleic Acid Therapeutics CDMO Market, \$Billion, 2022-2033

Figure 35: Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), \$Million, 2022-2033

Figure 36: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, \$Billion, 2022-2033

Figure 37: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), \$Million, 2022-2033

Figure 38: Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023

Figure 39: Funding Activities, January 2018-February 2023

Figure 40: New Offerings, January 2018-February 2023

Figure 41: Mergers and Acquisitions, January 2018-February 2023

Figure 42: Partnerships and Collaborations, January 2018-February 2023

Figure 43: Business Expansions, January 2018-February 2023

Figure 44: Regulatory and Legal Activities, January 2018-February 2023

Figure 45: Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, \$Billion, 2022

Figure 46: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market

Figure 47: AGC Biologics: Product Portfolio

Figure 48: AGC Biologics: Overall Financials, \$Million, 2019-2021

Figure 49: AGC Biologics: Segment Revenues, \$Million, 2019-2021

Figure 50: AGC Biologics: Net Revenue (by Region), \$Million, 2020-2021

Figure 51: BACHEM: Product Portfolio

Figure 52: BACHEM: Overall Financials, \$Million, 2020-2022

Figure 53: BACHEM: Net Revenues (by Segment), \$Million, 2020-2022

Figure 54: BACHEM: Net Revenue (by Region), \$Million, 2020-2022

Figure 55: BACHEM: R&D Expenditure, \$Million, 2020-2022

Figure 56: Eurofins Scientific: Product Portfolio

Figure 57: Eurofins Scientific: Overall Financials, \$Million, 2020-2022

Figure 58: Eurofins Scientific: Net Revenue (by Segment), \$Million, 2020-2022

Figure 59: Eurofins Scientific: Net Revenue (by Region), \$Million, 2020-2022

Figure 60: LGC Science Group Holdings Limited: Product Portfolio

Figure 61: LGC Science Group Holdings Limited: Overall Financials, \$Million, 2020-2022

Figure 62: LGC Science Group Holdings Limited: Net Revenue (by Segment), \$Million, 2021-2022

Figure 63: LGC Science Group Holdings Limited: Net Revenue (by Region), \$Million, 2020-2022

Figure 64: LGC Science Group Holdings Limited: R&D Expenditure, \$Million, 2020-2022

Figure 65: Merck KGaA: Product Portfolio

Figure 66: Merck KGaA: Overall Financials, \$Million, 2020-2022

Figure 67: Merck KGaA: Net Revenue (by Segment), \$Million, 2020-2022

Figure 68: Merck KGaA: Net Revenue (by Region), \$Million, 2020-2022

Figure 69: Merck KGaA: R&D Expenditure, \$Million, 2020-2022

## List Of Tables

### LIST OF TABLES

Table 1: Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023

Table 2: Key Questions Answered in the Report

Table 3: Some of the Partnerships and Collaborations in the Nucleic Acid Therapeutics CDMO Market

Table 4: Nucleic Acid Therapeutics CDMO Market, Key Investment

Table 5: Regulatory Organization: Nucleic Acid Therapeutics CDMO Market

Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021

Table 7: Advancements in Manufacturing Units of CDMO

Table 8: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis

## I would like to order

Product name: Europe Nucleic Acid Therapeutics CDMO Market: Analysis and Forecast, 2023-2033

Product link: <https://marketpublishers.com/r/EDF99B8B9E35EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EDF99B8B9E35EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970